OpenAI and the FDA are reportedly discussing AI for drug evaluations

OpenAI just met with the FDA to explore using AI—specifically a tool called cderGPT—to accelerate the drug approval process, according to Wired. While drug development can take over 10 years, this AI could fast-track final reviews. But what does this mean for the paper packaging industry? If AI speeds up drug launches, demand for compliant pharma packaging will spike faster than ever. That means tighter timelines for child-resistant cartons, tamper-evident seals, and FDA labeling compliance. Packaging converters, get ready—AI in pharma could be your new productivity pressure cooker.https://techcrunch.com/2025/05/07/openai-and-the-fda-are-reportedly-discussing-ai-for-drug-evaluations/

Comments

Popular posts from this blog

The Middle East Has Entered the AI Group Chat

US-Saudi $142 Billion Defense Deal Sparks Questions, Few Answers

Student Busts Teacher Using AI, Demands Tuition Refund